Spinal Anandamide Research Found Shared THC Cross-Tolerance Alongside Different Pharmacological Probe Responses

A 1995 study found similarities between THC, anandamide and fluoroanandamide in spinal antinociception, but also important differences in responses to pharmacological probes. Shared cross-tolerance did not establish identical mechanisms.

The routes and species were specific

Behavioral tests involved intrathecal administration in mice, while binding comparisons used rat spinal synaptosomes. Those are separate experimental systems. A direct spinal intervention cannot be equated with a person's exposure to inhaled or oral cannabis.

Several probe results diverged

Interventions affecting cyclic-AMP signaling attenuated THC responses but not the reported anandamide or fluoroanandamide responses. Other channel and opioid-antagonist comparisons also separated the compounds. Positive overlap on one test did not erase these null or contrasting findings.

A ligand could mimic and attenuate different responses

Anandamide shifted THC dose-response curves while also producing its own antinociceptive effects. The authors described both cannabinoid-like and blocking properties under the protocol. That does not mean the compound is a general-purpose antidote or that every downstream effect has one explanation.

Interpreting the evidence

The study supports comparing a panel of responses rather than inferring complete equivalence from shared binding or cross-tolerance. It does not supply human dose conversions, clinical analgesic advice or protection against cannabis impairment.

Related reading: interpreting cannabis tolerance claims.

Research reference

Welch SP; Dunlow LD; Patrick GS; Razdan RK (1995). Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. The Journal of pharmacology and experimental therapeutics. PubMed research record.

This analysis draws on the supplied study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us